Goserelin reduces ovarian failure associated with breast cancer chemotherapy, study shows

Treating women with the gonadotrophin releasing hormone agonist goserelin during chemotherapy for breast cancer significantly reduced the subsequent risk of ovarian failure and improved fertility, an international randomised trial reported in the New England Journal of Medicine has shown.1